Latest Conference Articles

October 21st 2018, 10:58pm

ESMO Congress: Lung Cancer

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.

October 21st 2018, 10:21pm

ESMO Congress: Breast Cancer

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

October 21st 2018, 10:20pm

ESMO Congress: Lung Cancer

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

October 21st 2018, 7:50pm

ESMO Congress: GU Cancers

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.

October 21st 2018, 7:32pm

ESMO Congress: GI Cancers

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses survival data with TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric cancer at the 2018 ESMO Congress.

October 21st 2018, 6:47pm

ESMO Congress: GU Cancers

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.

October 21st 2018, 1:38am

ESMO Congress: Gynecologic Cancers

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

October 21st 2018, 1:26am

ESMO Congress: Breast Cancer

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

October 21st 2018, 12:01am

ESMO Congress: Breast Cancer

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.

October 20th 2018, 9:35pm

ESMO Congress

Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.

October 20th 2018, 8:40pm

ESMO Congress: Breast Cancer

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

October 20th 2018, 7:04pm

ESMO Congress: Breast Cancer

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

October 20th 2018, 1:10pm

ESMO Congress: GU Cancers

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

October 20th 2018, 3:39am

ESMO Congress: GU Cancers

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

October 20th 2018, 12:18am

State of the Science Summit on Hematologic Malignancies

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

October 20th 2018, 12:16am

State of the Science Summit on Hematologic Malignancies

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

October 19th 2018, 11:27pm

ESMO Congress: Lung Cancer

MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant non–small cell lung cancer.

October 19th 2018, 6:00am

State of the Science Summit on Hematologic Malignancies

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

October 18th 2018, 12:09am

State of the Science Summit on GI Malignancies

Anthony B. El-Khoueiry, MD, discusses the promising hepatocellular carcinoma treatment paradigm.

October 17th 2018, 10:19pm

State of the Science Summit on GI Malignancies

Afsaneh Barzi, MD, discusses updates in the treatment of patients with pancreatic cancer, as well as the importance of genetic testing.